Author: toxlaw

Detecting ethanol does not, by itself, identify when or how it formed. A small 1984 experiment found low concentrations in germfree as well as conventional rats, supporting a source other than intestinal microbial fermentation. That finding concerns endogenous ethanol under rapidly processed experimental conditions. It does not establish postmortem production in a decomposed human body or supply a correction for an autopsy blood-alcohol result.

What question did the experiment test?

Jones, Ostrovsky, Wallin and Midtvedt compared five conventional and five germfree male Agus-strain rats. Mean body weight was 179 ± 14 g, reported as mean ± standard deviation. The germfree animals were reared and bacteriologically controlled under the study’s germfree conditions.

Food and water were withdrawn at approximately 08:30, and the animals were killed at about 11:30, three hours later. This was not an administered-ethanol challenge, a human drinking study or a prolonged decomposition experiment. Its question was whether intestinal microbes were necessary to explain the small ethanol concentrations measured in these animals.

Rapid preparation matters to interpretation

After decapitation, trunk blood was collected into heparinized tubes. A 1 mL blood aliquot was mixed immediately with 0.5 mL of 33% perchloric acid and 0.1 mL of 1 M thiourea. The interval from killing to blood protein precipitation was approximately one minute.

Liver, both kidneys and the whole brain were rapidly removed and placed on ice. A weighed liver portion of about 2 g, the kidneys and brain were homogenized in ice-cold perchloric acid. Conventional and germfree specimens received the same handling. These procedures are fundamentally different from leaving a body or collected blood for hours or days to study microbial ethanol formation.

What did the concentrations show?

In germfree rats, mean ethanol concentrations were 4.2 ± 0.19 µM in whole blood, 5.1 ± 0.55 µM in liver, 8.2 ± 0.59 µM in kidney and 4.4 ± 0.17 µM in brain. These uncertainties were reported as standard errors, not standard deviations. The units are micromolar; they must not be rewritten as mg/mL or g/L.

The two-way analysis of variance found no statistically significant overall difference between conventional and germfree groups: F(1,28) = 0.19, p > 0.05. There was a significant difference among specimen types, F(3,28) = 61.9, p < 0.001, driven by higher kidney concentrations. The kidney pattern occurred in both groups.

With only five animals per group, a nonsignificant comparison does not prove exact equivalence or establish that microbes never contribute to ethanol. The positive observation is that ethanol remained measurable under germfree conditions. The authors interpreted that as supporting a nonmicrobial endogenous source, rather than an exclusively gastrointestinal microbial origin.

What did the analytical method establish?

The investigators used headspace gas chromatography with flame-ionization detection and a packed Porapak Q column. Volatiles were assigned by retention times compared with standards; this was not mass-spectrometric confirmation. Potassium carbonate was used to increase transfer into the headspace, and the sealed vials equilibrated for 30 minutes at 60°C.

Aqueous ethanol calibration covered 100–500 µg/L, equivalent to 2.17–10.85 µM. Reported calibration correlations were 0.98–0.99, and the coefficient of variation was 4.2% at 275 µg/L in water. The calculation assumed equivalent headspace partitioning for aqueous standards and prepared specimen supernatants.

The paper did not provide a complete modern validation dataset with separate numerical detection and quantitation limits for every matrix. Its calibration performance should not be presented as universal forensic-method validation. Likewise, agreement with a retention standard identifies an analytical peak under the stated conditions; it does not independently establish the biological source of that ethanol.

Why this cannot correct a human autopsy result

The experiment did not measure ethanol formation over a postmortem time course, examine decomposed human specimens or test preservative failure during storage. It therefore supplies no validated amount to subtract from a human blood result, no production rate and no threshold distinguishing drinking from postmortem fermentation.

Three questions must remain separate: whether small amounts can arise through endogenous metabolism, whether microbes can produce ethanol after death or collection, and whether a particular person consumed alcohol. Evidence supporting the first does not answer the other two in an individual case. Species, diet, fasting, collection and analytical conditions also limit extrapolation.

A case opinion should preserve the actual specimen, units, handling record and evidence bearing on origin. The rat observations establish neither impairment in a human nor alcohol’s contribution to a death.

For a human case with a different design, see serial ethanol increases in preserved postmortem blood. That report examined change during later testing; the germfree-rat experiment did not.

Primary source

Jones AW, Ostrovsky YuM, Wallin A, Midtvedt T. Lack of differences in blood and tissue concentrations of endogenous ethanol in conventional and germfree rats. Alcohol. 1984;1(5):393–396. doi:10.1016/0741-8329(84)90009-0.

Clonazepam and several related urinary metabolites could not, by themselves, establish clonazafone ingestion in a published forensic investigation. The investigators found three candidate metabolites in comparison urine samples with declared clonazepam intake as well. Even the proposed intermediate desglycylclonazafone was not unique evidence, because it can form from clonazepam in a pH-dependent equilibrium.

Why identifying a prodrug presents a separate question

Clonazafone can be converted to clonazepam through desglycylclonazafone. Detecting the downstream drug therefore raises at least two possible explanations: clonazepam intake itself or exposure to a precursor that produces it. Distinguishing those explanations requires a sufficiently specific finding, not simply a signal chemically related to clonazepam.

Malzacher and colleagues investigated one fatal mixed-intoxication case involving a 20-year-old man. Autopsy specimens were collected about 20 hours after death, after the body had been cooled to 5°C beginning six hours after death. For the specificity comparison, the researchers also examined three anonymized antemortem routine urine samples with declared clonazepam intake. Those three samples were not an independently randomized control population and did not come from three comparable postmortem cases.

What did the comparison samples show?

The investigated candidates included 2-amino-2′-chloro-5-nitrobenzophenone, its hydroxy derivative and a glucuronide of the hydroxy derivative. The paper labels these C6, C5 and C3, respectively. All three were also present in the routine clonazepam urines.

That finding directly limits specificity. Those compounds may be useful analytical targets for investigating related exposure, but their presence cannot be treated as unique proof that clonazafone rather than clonazepam was consumed. The three comparison samples are too few to estimate diagnostic sensitivity or specificity numerically, and declared intake does not supply the control offered by a fully documented administration experiment.

The strongest prodrug-specific finding in the fatal case was detection of parent clonazafone itself in urine, supported by comparison with reference material. The authors concluded that detected clonazepam probably resulted at least partly from clonazafone intake. They did not establish that all clonazepam must have come from that source or exclude additional clonazepam use.

Why the intermediate was not decisive

Desglycylclonazafone was detected in the investigation. However, the authors explained that this compound can also form from clonazepam in an equilibrium reaction at acidic pH. Its position on the proposed forward metabolic pathway did not make its presence exclusive to prodrug ingestion.

The case blood pH was 6.8. The paper identified pH, possible continued conversion after death or collection, and the lack of clonazafone postmortem-stability data as uncertainties. These observations do not establish the amount formed after death. They do prevent interpreting the intermediate as an unambiguous record of the original administered substance.

How strong was the analytical identification?

LC–high-resolution MS used molecular and fragment information, a characteristic chlorine isotope pattern for relevant compounds, and a mass-error requirement below 2 parts per million. Clonazafone and clonazepam identities were checked against MS/MS spectra generated from reference substances. The proposed metabolites were tentatively identified from fragmentation and related evidence.

“Tentatively identified” should remain attached to those metabolite assignments. A narrow mass error and plausible fragmentation are useful evidence, but do not confer the same identification certainty as every available authentic-standard comparison. Nor does chemical identification alone establish which parent generated a shared metabolite.

Targeted clonazafone measurements were semiquantitative, using seized material rather than certified reference material. The authors did not complete full validation. Those limitations concern quantitative certainty and method characterization; they are separate from the biological question of marker specificity.

Hydrolysis did not resolve the source

Phase II conjugates of parent clonazafone were not detected with the presented method. Enzymatic hydrolysis did not produce a reported significant increase in clonazafone. This was a finding in one case, not a population trial demonstrating absence of conjugation under all circumstances.

The study also did not validate a parent-to-metabolite ratio for estimating time since ingestion. Postmortem conversion, specimen history and the analytical response of different compounds would need to be addressed before making such a claim.

What should an interpretation retain?

A defensible account separates the confirmed parent finding, tentative metabolite assignments, comparison-sample evidence and possible postmortem chemistry. A shared metabolite supports a narrower conclusion than a unique marker. None of these findings independently measures impairment or assigns a causal contribution to death.

For the broader analytical distinction, see why accurate mass alone does not settle drug identity. A separate example concerns a metabolite shared by several nitazene parents.

Primary source

Malzacher J, Pulver B, Heller N, et al. Fatal intoxication involving amphetamine, clonazafone, a benzodiazepine prodrug, and fluoro-etonitazene, a new synthetic opioid. International Journal of Legal Medicine. 2026;140:769–778. Published online October 20, 2025. doi:10.1007/s00414-025-03627-7.

A negative postmortem blood result did not exclude clonazafone exposure in a published mixed-intoxication case. Targeted testing found this benzodiazepine prodrug in urine, thigh muscle and stomach contents, while femoral blood, heart blood and vitreous humor were reported negative for the parent compound. The case supports specimen-specific investigation, not a universal ranking of matrices or a measured false-negative rate.

The case and the collection interval

Malzacher and colleagues described one 20-year-old man who died after unsuccessful resuscitation. Clonazafone powder and a liquid containing fluoro-etonitazene were recovered from the scene and chemically characterized. Clonazafone is a prodrug that can be converted through an intermediate to clonazepam.

The body was cooled to 5°C six hours after death and remained cooled for 14 hours before autopsy, approximately 20 hours after death. Specimens included femoral blood, heart blood, urine, vitreous humor, stomach contents and thigh muscle. These are the conditions of one investigation, not a controlled comparison across postmortem intervals or decomposition stages.

What was found in each matrix?

Duplicate targeted LC–MS/MS measurements gave semiquantitative clonazafone estimates of 39 ng/mL in urine, 3.0 ng/g in muscle and 76,000 ng/mL in stomach contents. Urine after glucuronidase digestion was reported at 50 ng/mL. Parent clonazafone was not detected in femoral blood, heart blood or vitreous humor; the authors cited a lower quantitation limit of 0.1 ng/mL for the blood method.

A lower quantitation limit is not automatically an independently established detection limit. “Not detected” should retain the particular assay and specimen context. It does not establish that the compound had never been present during life.

Stomach contents totaled approximately 150 mL, corresponding to about 11 mg clonazafone remaining there using the reported estimate. This residual amount is not a reconstructed swallowed dose. It omits any absorbed or eliminated material, and the authors noted that gastric accumulation could have more than one explanation. The findings did not independently prove an administration route.

Why the numerical results require qualification

Certified reference material was unavailable. The investigators used seized clonazafone powder that showed no impurities by GC–MS and infrared analysis and treated it as relatively pure material suitable for semiquantification. Clonazepam-d4 served as the internal standard.

The blood calibration range was 0.1–100 ng/mL. A separate urine calibration covered 50–1,200 ng/mL, and diluted stomach contents were evaluated using that calibration. Notably, the reported urine estimate of 39 ng/mL was below the lowest stated urine calibrator. It should remain an approximate semiquantitative result, rather than being presented as a fully validated quantitative concentration within that urine range.

Ten blank blood samples and two zero samples showed no interfering signals with clonazafone or its internal standard. That selectivity check is useful but is not complete validation in every matrix. The authors explicitly reported that full validation was not performed and that insufficient case material prevented the more accurate standard-addition approach they had considered.

Broad screening and targeted testing did different work

The investigation included routine urine immunoassay screening, instrumental screening and targeted analysis. High-resolution MS detected parent clonazafone in urine and stomach contents; the targeted procedure separately detected it in muscle. The high-resolution work described for this investigation covered blood, urine and stomach contents, rather than the same complete specimen set as targeted testing. These findings are not a controlled comparison of the two procedures’ sensitivity in muscle. Each result must retain its actual specimen and analytical workflow.

Routine quantitative femoral-blood analysis found clonazepam at 1.5 ng/mL and 7-aminoclonazepam at 140 ng/mL. These are different analytes from clonazafone. The authors cautioned that bacterial conversion of clonazepam after death and possible continued prodrug conversion could alter the pattern; clonazafone postmortem-stability data were unavailable. The measurements cannot be read as a validated clock for ingestion or concentrations at the instant of death.

What did the case establish about death?

The reported cause was combined intoxication involving fluoro-etonitazene, clonazepam and amphetamine. Pulmonary and cerebral edema were among the autopsy findings considered. That integrated conclusion should not be reduced to “clonazafone was present, therefore it alone caused death.” This single case supplied neither a clonazafone fatal-concentration threshold nor an impairment threshold.

In reviewing a similar investigation, the useful questions concern which specimens remain, which parent and metabolite targets were tested, the sensitivity of each workflow, reference-material quality and the distinction between approximate and validated quantitative results.

See also vitreous humor versus blood for screening and why a negative autopsy drug screen has a defined scope.

Primary source

Malzacher J, Pulver B, Heller N, et al. Fatal intoxication involving amphetamine, clonazafone, a benzodiazepine prodrug, and fluoro-etonitazene, a new synthetic opioid. International Journal of Legal Medicine. 2026;140:769–778. Published online October 20, 2025. doi:10.1007/s00414-025-03627-7.

A finding that clozapine contributed to death in approximately 45% of a selected autopsy series does not mean that 45% of people taking clozapine will die from it. In a 2026 study, the numerator was 20 cases with an attributed causal role and the denominator was 44 clozapine-positive autopsies with paired blood and brain quantification. The study did not follow a population of treated patients.

Who was eligible to enter the study?

Van der Meer and colleagues reviewed Copenhagen forensic cases investigated from late 2014 to early 2026. The overall study included 466 autopsy cases involving one or more of four antipsychotics. Entry required quantification of a selected drug in both blood and brain. Clozapine was quantified in 44 cases.

This selection excludes living recipients and does not enumerate everyone prescribed clozapine in the source population. It also requires suitable paired specimens and measurable drug. Consequently, 20/44 describes attribution within the included autopsies, not the probability of fatal poisoning after a prescription, the risk per dose or the frequency of death among all exposed people.

What did “contributed to death” include?

Class A meant that the antipsychotic was the sole cause of death. Class B meant contribution together with other pharmaceuticals, drugs of abuse, alcohol or disease. Class C meant no attributed contribution. For clozapine, there were 12 class A cases, eight class B cases and 24 class C cases.

The approximately 45% figure combines A and B: 20/44. It should not be relabeled as 20 deaths caused by clozapine alone. Conversely, the 24 class C cases were deaths in which clozapine was detected without an attributed causal role; they were not living, symptom-free control patients.

Two forensic toxicologists evaluated the analytical findings in the original investigations, and the forensic pathologist determined the final cause with case circumstances. A toxicologist assigned the study categories from those conclusions and toxicity remarks. These were case-based judgments incorporating toxicology, not outcomes established independently of the concentrations being compared.

Concentrations helped interpretation without creating a universal cutoff

The combined A+B clozapine group had a median blood concentration of 3.1 mg/kg, with 10th–90th percentiles of 1.4–7.1 mg/kg. Its median brain concentration was 8.5 mg/kg, with percentiles of 3.4–17 mg/kg. In class C, the corresponding medians were 1.3 mg/kg in blood and 2.9 mg/kg in brain, with percentile intervals of 0.16–2.8 and 0.59–8.2 mg/kg.

The higher medians in attributed cases are useful descriptive findings. The overlapping intervals prevent interpreting the group summaries as an infallible individual boundary. They are percentile intervals rather than full ranges, and a class C observation does not prove that the same concentration would be harmless in another person with different co-exposures or disease.

The median brain–blood ratio was 3.0 in A+B and 2.8 in C. Across the four drugs, ratios did not differ significantly between causal categories. Neither a positive finding nor a ratio near the group median supplied an independent cause-of-death test.

Why collection and analytical conditions remain relevant

Blood was collected from the femoral site without iliac-vein ligation, using 4–8 mL tubes with sodium fluoride and potassium oxalate. Frontal cerebral cortex was sampled for brain analysis, with grey matter separated when feasible. Bodies were kept at 5°C after arrival, autopsy generally occurred within four days of arrival, and specimens were stored at −20°C. The actual postmortem intervals were unavailable, preventing assessment of redistribution over time.

UHPLC–MS/MS quantification used blood calibrators and quality controls in both matrices. For clozapine, the reported measurement range was 0.005–0.20 mg/kg. Brain quality-control imprecision at 0.25 mg/kg was 11.6% across 89 measurements. The authors acknowledged uncertainty from tissue composition, mixed tissue in advanced decomposition, calibration and possible drug interactions. These factors limit how directly another specimen can be compared with the reference data.

Can the percentage rank antipsychotics by danger?

The study reported a larger attributed proportion for clozapine than for the other included antipsychotics. That observation is not, on its own, a comparative risk estimate for prescribing. The drug groups differed in size and were selected from deaths; there were no matched exposure denominators accounting for the number, duration and characteristics of treated patients.

A defensible opinion identifies the actual question: how frequently clozapine was judged relevant among these selected autopsies. Estimating a patient’s treatment-related mortality, an individual fatal dose or the probability that a particular result caused death would require additional evidence.

For a broader example of the difference between drug detection and fatal intoxication, see the 2,996-case autopsy screening study.

Primary source

van der Meer MZ, Rasmussen BS, Nedahl M, Nielsen MKK. From blood to brain: postmortem brain concentrations and brain–blood ratios of chlorprothixene, clozapine, olanzapine, and quetiapine. Journal of Analytical Toxicology. 2026;50(7):bkag065. doi:10.1093/jat/bkag065.

A brain–blood ratio near three can help place a postmortem quetiapine result in the context of comparable autopsy findings. It cannot supply an exact blood concentration when blood is missing, recover the concentration during life, or decide whether quetiapine caused death. A 2026 Copenhagen study found a median ratio of 3.0 in 226 quetiapine cases, with substantial variation around that median.

What specimens produced the reference data?

Van der Meer and colleagues retrospectively reviewed 466 autopsy cases investigated from late 2014 to early 2026. Inclusion required quantification in both blood and brain of at least one of four antipsychotics. Quetiapine accounted for 226 cases; the other drug groups were not separate, mutually exclusive populations.

Bodies were refrigerated at 5°C on arrival, and autopsy usually occurred within four days of arrival. That interval is not a documented death-to-autopsy interval. The investigators lacked the postmortem-interval information needed to assess redistribution over time.

Femoral blood was collected without ligation of the iliac vein, in one or two 4–8 mL tubes containing 100 mg sodium fluoride and 22.5 mg potassium oxalate. Brain specimens were 5–20 g portions of frontal-lobe cerebral cortex. For analysis, 500 mg of grey matter was manually separated and homogenized with water at 1:3. Biological material was stored at −20°C before analysis.

The median describes a distribution, not a fixed conversion

Across the quetiapine cases, median blood concentration was 0.10 mg/kg, with 10th–90th percentiles of 0.015–1.5 mg/kg. Median brain concentration was 0.34 mg/kg, with corresponding percentiles of 0.037–4.1 mg/kg. The median of the individual brain–blood ratios was 3.0, with 10th–90th percentiles of 1.5–5.0.

These percentile intervals describe the middle 80% of observations; they are neither full observed ranges nor confidence intervals. Also, dividing the two group medians is not the same calculation as taking the median of individual paired ratios.

Consider an illustrative brain result of 3 mg/kg. Dividing by three yields a numerical estimate of 1 mg/kg blood, but does not turn that estimate into a measured specimen result. The observed variation in ratios alone prevents calling that reconstruction exact. Nor was the study a validation of individual blood prediction from brain tissue.

Did the ratio distinguish fatal involvement?

The authors classified five quetiapine cases as sole-cause intoxications, 28 as contributing with other drugs or disease, and 193 as cases without quetiapine contribution. Combining the first two categories gave 33 cases with an attributed role in death.

In those 33 cases, median brain concentration was 2.9 mg/kg and median blood concentration was 0.74 mg/kg. In the 193 cases without attributed contribution, the medians were 0.26 and 0.088 mg/kg, respectively. However, the brain–blood ratio medians were much closer: 3.3 versus 2.9. The study reported no statistically significant differences in ratios between the causal categories for any of the four drugs.

That null finding does not establish that the categories were identical. It does show why a ratio near three is not a demonstrated diagnostic boundary between poisoning and incidental detection. The authors also described overlapping concentrations across causal categories.

Quantification had analytical support and tissue limits

Testing used automated solid-phase extraction followed by UHPLC–MS/MS, deuterated internal standards, blood-based calibrators, and quality controls in blood and brain. The reported quetiapine measurement range was 0.005–0.20 mg/kg. Brain quality control at 0.25 mg/kg had a coefficient of variation of 10.2% across 91 measurements; blood controls at 0.01 and 0.5 mg/kg had coefficients of variation of 10.7% and 7.5%.

These performance data concern the analytical procedure. They do not eliminate biological variation or establish that all brain samples have equivalent composition. In advanced decomposition, grey and white matter could not always be separated, and mixed tissue was analyzed. The authors identified tissue composition, matrix effects, extraction efficiency and blood-based calibration as relevant uncertainties.

How should the result be used?

Retain the anatomical brain region, tissue preparation, units, collection conditions and method when comparing a case with this dataset. A complementary brain result can be valuable when blood is unavailable, but should remain identified as a brain measurement. It is not a direct measure of unbound drug at a receptor, observed impairment, ingested dose or antemortem concentration.

For related specimen issues, see the limits of interpreting THC in brain tissue and why similarity between two postmortem specimens does not establish an antemortem concentration.

Primary source

van der Meer MZ, Rasmussen BS, Nedahl M, Nielsen MKK. From blood to brain: postmortem brain concentrations and brain–blood ratios of chlorprothixene, clozapine, olanzapine, and quetiapine. Journal of Analytical Toxicology. 2026;50(7):bkag065. doi:10.1093/jat/bkag065.

A historical human experiment found that oral methamphetamine could improve later picture recognition in one sleep-defined subgroup. But a more specific claim—that the drug preferentially improved emotional rather than neutral memory—requires care. The paper reported no significant dose-by-valence interaction, even though separate analyses produced significant results for emotional pictures and a null result for neutral pictures. Those are different statistical questions.

What did the 2015 experiment actually compare?

Ballard and colleagues randomly assigned 60 healthy young adults to two timing groups. The encoding group included 29 participants and received placebo, 10 mg, and 20 mg oral d-methamphetamine across counterbalanced, double-blind sessions, with active drug given 45 minutes before picture viewing. The consolidation group included 31 participants and received the same dose conditions immediately after viewing. Recognition was tested two days later, without drug administration at that visit.

Each picture set contained 60 images: 20 positive, 20 neutral, and 20 negative. Recognition accuracy was calculated as the hit rate minus the false-alarm rate. Thus, the outcome accounted for incorrectly calling an unstudied picture familiar; it was not simply the number of pictures a participant said they remembered.

Why do the subgroup denominators matter?

The investigators divided participants using reported sleep after the 20-mg session. There were 31 adequate sleepers and 29 poor sleepers overall. Within the encoding group, those numbers were only 14 and 15, respectively. The consolidation group contained 17 adequate and 14 poor sleepers. The relevant denominator for a result in adequate sleepers given drug before viewing was therefore 14, not 60.

The paper generally describes the sleep boundary as at least six hours versus less than six hours, including in its abstract and table note. Its Results prose instead describes over six hours versus six hours or less. That internal inconsistency means a reader should not silently assign a participant reporting exactly six hours to a category without clarification. It does not erase the reported group results, but it matters when attempting to reproduce the classification.

Sleep category was also based on a post-dose self-report, rather than randomized sleep assignment. Consequently, the subgroup comparison cannot establish that prescribing a particular amount of sleep would cause the observed memory benefit or prevent impairment.

What was significant, and what was not?

For encoding-group recognition accuracy, the reported dose-by-sleep interaction was significant: F(1,27) = 16.01, p < .001. Compared with placebo, 20 mg improved overall accuracy among adequate sleepers (p = .015) and impaired it among poor sleepers (p = .011). The corresponding 10-mg comparisons were not significant (p = .393 and p = .956). A statement that both tested doses improved memory would therefore misstate the findings.

Among adequate sleepers, separate analyses found improved accuracy for positive pictures at 20 mg (p = .015) and negative pictures (p = .024); the analysis of neutral pictures was null (p = .85). However, the authors expressly reported that there was no dose-by-valence interaction. They then examined categories separately for comparison with their previous amphetamine work.

That distinction is central. A significant drug-placebo comparison for emotional pictures and a nonsignificant comparison for neutral pictures do not, by themselves, establish that the drug effects differ between those picture categories. An interaction addresses that difference more directly. The observed pattern can motivate an emotional-specificity hypothesis, while the null interaction limits how confidently the hypothesis can be asserted.

Why must the post-learning null result stay in the account?

When methamphetamine was given only after picture viewing, the main reported analyses found no effect on recognition accuracy and no modification by sleep category or picture valence (p values > .10). The experiment therefore did not demonstrate a general memory-consolidation benefit from administering the drug after learning.

Even the timing comparison has a limit: different participants formed the encoding and consolidation groups. Every participant crossed over between doses within their assigned timing condition, but the same people were not tested under both pre-viewing and post-viewing drug administration. Furthermore, a dose given before viewing could influence both initial encoding and subsequent consolidation; that condition does not isolate encoding alone.

What can an expert reasonably conclude?

The defensible interpretation preserves both the benefit and its boundaries: under this controlled oral-dose protocol, later recognition improved in a small, self-reported adequate-sleep subgroup at 20 mg, while the poor-sleep subgroup worsened. Emotional-category results suggested a pattern worth investigating, but did not establish selective emotional enhancement through a significant interaction.

These were healthy volunteers recognizing standardized images, not witnesses reconstructing an event or drivers responding to road hazards. No blood concentration threshold for memory accuracy, credibility, or driving impairment was established. Applying this historical experiment to an individual requires an explanation of the task, dose, route, timing, sleep history, and uncertainty rather than a categorical claim that methamphetamine improves—or destroys—memory.

Source

Ballard ME, Weafer J, Gallo DA, de Wit H. Effects of Acute Methamphetamine on Emotional Memory Formation in Humans: Encoding vs Consolidation. PLOS ONE. 2015;10(2):e0117062. Published February 13, 2015. doi:10.1371/journal.pone.0117062. Original controlled human experiment; historical evidence. Commentary above is an analysis of the supplied full-text paper, not a clinical recommendation.

Detecting 4′-hydroxy nitazene can support investigation of nitazene exposure, but the metabolite alone does not identify one unique parent drug. Several structurally related nitazenes can produce it. A forensic method and casework study included a specimen with two plausible parent compounds, leaving the metabolite’s source unresolved.

Why a shared target is useful and limited

Walton and colleagues described 4′-hydroxy nitazene as a common metabolite of nitazene analogs possessing the relevant nitro group, diethylamine component and phenyl-ether structure. Their analysis therefore supported including it in a broader testing strategy.

The same shared origin creates a limit: in the absence of a parent-specific finding, identification of this metabolite cannot distinguish among every compatible parent. The term “shared” also should not be extended to every possible nitazene derivative regardless of structure. The paper described a chemically defined scope.

The selected authentic casework

The investigators received 171 biological specimens from 114 investigations suspected of involving new synthetic opioids during 2019–2021. These included 47 postmortem cases and 67 driving-under-the-influence cases. Postmortem specimens comprised peripheral, central and unspecified blood, serum, urine, bile, liver, brain and vitreous fluid.

These were selected referrals, not a population prevalence survey. Multiple specimens could come from one person, and the sample count cannot be read as 171 independent deaths. The study did not provide one uniform postmortem interval or collection history applicable to every specimen.

What the shared-metabolite findings showed

The authors reported 4′-hydroxy nitazene with isotonitazene, metonitazene, protonitazene and butonitazene in postmortem specimens. In one sample containing both metonitazene and butonitazene, they could not attribute the shared metabolite to one parent. Both were plausible sources.

Table IV included three quantitative bile results for 4′-hydroxy nitazene, with a median of 52 ng/mL and range of 43–98 ng/mL. Blood findings were frequently qualitative below the quantitation limit. The bile values do not supply a blood-concentration conversion or establish which parent produced what fraction of the metabolite.

Urine results included both qualitative and quantitative findings. A larger concentration in an excretory matrix cannot be treated as a direct measure of effect at the brain or as a dose reconstruction. Differences between matrices can reflect several biological and analytical influences.

Identification and quantitation were separate claims

The validated LC–tandem quadrupole method had a detection limit of 0.1 ng/mL for 4′-hydroxy nitazene, with a quantitation limit of 0.5 ng/mL and calibration range of 0.5–50 ng/mL. Findings below the quantitation limit could be confirmed qualitatively without a supported exact numerical concentration.

Blood and urine received specific validation assessments. Other matrices, including bile, were analyzed using standard addition. This accommodated difficult alternative matrices but did not make their full validation history identical to that of blood. Extraction recovery exceeded 85% for the original validated panel, and matrix enhancement was assessed rather than assumed absent.

The paper separately demonstrated the need to chromatographically distinguish isotonitazene from protonitazene, positional isomers that cannot be distinguished by mass spectra alone under the method. Parent-drug identification therefore required its own analytical evidence; the shared metabolite could not substitute for it.

What cannot be inferred from the pattern alone

The study did not establish a controlled metabolite-ratio clock for time since ingestion. Authentic storage histories varied considerably, and metabolite behavior was matrix-dependent. A metabolite result cannot independently establish whether a parent concentration changed after death.

Nor does detecting a metabolite establish the magnitude of impairment or its contribution to death. Those conclusions require additional pharmacological, specimen and case evidence. The defensible statement retains the identified compound, matrix, confirmation status and whether the result was qualitative or quantitative.

For related distinctions, see compound identification by mass spectrometry and the limits of a negative drug screen.

Primary source

Walton SE, Krotulski AJ, Logan BK. A Forward-Thinking Approach to Addressing the New Synthetic Opioid 2-Benzylbenzimidazole Nitazene Analogs by Liquid Chromatography–Tandem Quadrupole Mass Spectrometry (LC–QQQ-MS). Journal of Analytical Toxicology. 2022;46:221–231. https://doi.org/10.1093/jat/bkab117.

Freezing should not be assumed to preserve every nitazene better than refrigeration without analyte-specific evidence. A 2022 method study found generally useful refrigerated stability, inconsistent frozen results and an important problem with 5-amino isotonitazene. The results support checking the actual validation conditions, not declaring freezing harmful for all nitazenes or all postmortem specimens.

A controlled blood experiment, not a decomposition series

Walton, Krotulski and Logan fortified drug-free blood with nine nitazene analytes, including parent drugs and isotonitazene metabolites, at 10 ng/mL. Aliquots of 0.5 mL were stored at −20°C, 4°C or approximately 20°C. Samples were extracted and analyzed in triplicate at baseline, 24 and 48 hours, and 7, 14, 28 and 60 days.

Fresh calibration and controls were prepared for each analysis. Stability required remaining within a 20% concentration-change criterion and meeting the necessary identification and quantitation criteria. The experiment did not reproduce microbial contamination or chemical complexity across a series of decomposed human blood specimens.

The principal findings and their limits

The authors reported refrigerated stability for the tested analytes except 5-amino isotonitazene, and concluded that suspected nitazene blood could generally be refrigerated at 4°C for at least 28 days on the evidence generated. Several analytes showed earlier instability at room temperature. Frozen results were inconsistent, with most parent drugs showing instability after 28 days; the authors called for further assessment.

Those findings do not justify a universal numerical loss correction or a claim that a particular frozen case sample must be inaccurate. Only one fortified concentration and the stated storage conditions were tested. Results at 10 ng/mL do not establish identical behavior near the detection limit, in every container or in every biological matrix.

The problematic 5-amino isotonitazene results require particular care: calibration/control accuracy failed during the stability assessment. The authors suspected poor stability but described that attribution as anecdotal and requiring further work. An assay that fails quantitative criteria cannot supply a reliable degradation curve merely because a signal remains visible.

Processed extracts were a different stability question

The same paper assessed prepared extracts retained in the autosampler. Isotonitazene, protonitazene, etonitazene, clonitazene, flunitazene and N-desethyl isotonitazene met the stated stability conditions for up to 216 hours. The reported interval for 5-amino isotonitazene was 192 hours; metonitazene and 4′-hydroxy nitazene had shorter stability windows.

These autosampler observations concern processed analytical material. They do not extend the storage life of unextracted blood, urine, bile or tissue. Conversely, an acceptable refrigerated blood result does not guarantee that an extract can wait indefinitely before injection.

Other validation exceptions remained relevant

The full assay used LC–tandem quadrupole mass spectrometry. Detection limits were 0.1 ng/mL. Most analytes had a 0.5-ng/mL quantitation limit and a 0.5–50-ng/mL calibration range. For 5-amino isotonitazene, the quantitation limit and lowest calibrator were 1.0 ng/mL.

That metabolite also failed dilution and urine matrix-matching assessments. The authors limited its validated use to undiluted blood. This is an analyte-specific restriction; successful validation of other members of the panel did not remove it.

Why case storage history matters

The authentic casework component contained 171 specimens from 114 selected investigations, including 47 postmortem and 67 driving cases. Specimen storage before analysis varied from less than a month to approximately a year. Those histories exceeded the controlled stability experiment in some instances and did not establish that every authentic result was unaffected by storage.

A report review should distinguish specimen stability, extract stability, valid quantitative measurement and biological interpretation. A detected drug does not by itself establish impairment or cause of death, and a later negative result does not reconstruct an earlier concentration without evidence.

Related examples include GHB change in stored postmortem blood and serial ethanol measurements in a preserved specimen. Their mechanisms and analytes are different; their relevance is the need to examine actual handling evidence.

Primary source

Walton SE, Krotulski AJ, Logan BK. A Forward-Thinking Approach to Addressing the New Synthetic Opioid 2-Benzylbenzimidazole Nitazene Analogs by Liquid Chromatography–Tandem Quadrupole Mass Spectrometry (LC–QQQ-MS). Journal of Analytical Toxicology. 2022;46:221–231. https://doi.org/10.1093/jat/bkab117.

A drug listed in a postmortem surveillance study may be a confirmed finding or an explicitly unconfirmed screening result. Those categories should remain distinct. In a 4,395-case Ontario fentanyl series, some newly encountered substances were reported after a single analytical run, and the authors included those findings with that qualification.

What population the counts describe

The retrospective study covered investigations submitted to the Centre of Forensic Sciences between January 2020 and December 2022. Inclusion required fentanyl quantified above 1.3 ng/mL in autopsy blood from an intact vessel or an antemortem hospital sample. Most specimens were femoral blood, but approximately 11% were heart blood, hospital samples or an unspecified source.

The series was selected for measurable fentanyl. It cannot estimate the prevalence of another drug among all deaths, all drug users or the general population. There was also no living comparison group from which to calculate the added fatal risk of a particular combination.

The study’s confirmation rule

Drug screening used liquid chromatography–quadrupole time-of-flight mass spectrometry, or LC–QTOF-MS. Under the laboratory’s reporting criteria, a detected drug was supported either by two independent LC–QTOF-MS analyses or by one LC–QTOF-MS analysis plus an orthogonal method, such as GC–MS or LC–MS/MS.

A small proportion of findings, described as less than 5%, were supplied to clients after a single LC–QTOF-MS analysis and labeled unconfirmed. A client could request follow-up testing. The article explained that the service selected and the needs of the death investigation influenced how extensively all detected compounds were pursued.

Thus, “confirmed” did not necessarily mean two different instrument technologies: two independent LC–QTOF-MS analyses also met the stated rule. Conversely, a plausible single-run signal did not become confirmed merely because other drugs in that case were confirmed.

The counts need their analytical labels

The study reported frequent co-occurrence of novel benzodiazepines, including etizolam in 642 cases, flualprazolam in 531 and bromazolam in 138. Synthetic opioid findings included isotonitazene in 30 cases and metonitazene in 27. Confirmation patterns varied across compounds and time.

Six protonitazene findings were reported only as unconfirmed results. They should not be restated as six fully confirmed protonitazene deaths. Nor does the absence of completed confirmation prove that those detections were false. It limits the strength of the identification claim available from this dataset.

In the selected case with estimated fentanyl above 2,000 ng/mL, acetylfentanyl, bromazolam, cocaethylene and metonitazene were identified by LC–QTOF-MS but not confirmed by a second independent analysis. The authors preserved that qualification while reporting mixed drug intoxication as the cause of death.

Testing practices affect apparent trends

A rising count can reflect changes in exposure, analytical scope, identification capability, follow-up testing or some combination of these. The paper specifically identified the proliferation of new substances and reporting practices as interpretive challenges. It did not establish a numerical correction that separates those influences.

The fentanyl quantitation method had its own detection limits, which changed during the study, while the LC–QTOF-MS screen used predefined identification criteria rather than a single stated detection limit. The quantitative fentanyl inclusion rule cannot be treated as the sensitivity threshold for every co-occurring substance.

The available histories also did not establish the source of fentanyl in every case. Co-detection alone does not show that substances came from one product, were deliberately combined or were consumed at the same moment.

What a defensible summary says

A useful summary identifies the selected cohort, specimen mix, reporting category and confirmation status. It distinguishes a laboratory signal from a quantified concentration, and both from the pathologist’s assessment of contribution to death.

For related testing-scope questions, see why an opiate screen may not test for fentanyl and what a negative autopsy screen can exclude. Neither positive nor negative results answer more than the method and case evidence support.

Primary source

Adamo A, Marshall K, Woodall KL. Fentanyl-related deaths in Ontario, Canada: toxicological findings and circumstances of death in 4395 cases (2020–22). Journal of Analytical Toxicology. 2024;48:598–605. https://doi.org/10.1093/jat/bkae061.

A fentanyl result reported as “greater than 40 ng/mL” supplies a lower bound, not an exact concentration of 40 ng/mL. A large Ontario death-investigation series illustrates why the distinction matters: most results above the method’s upper quantitation limit were not converted into exact measurements by dilution and reanalysis.

The selected population

Adamo, Marshall and Woodall reviewed 4,395 investigations submitted to Ontario’s Centre of Forensic Sciences during 2020–2022 in which fentanyl was quantified above the study’s 1.3-ng/mL inclusion threshold. The laboratory received 21,809 medicolegal investigations over that period. The 4,395 cases therefore represent a selected fentanyl-positive death-investigation dataset, not all deaths or all people exposed to fentanyl.

Most analyzed specimens were femoral blood: 3,898, or 89%. The remainder included heart blood, hospital samples and specimens with an unspecified source. Inclusion allowed autopsy blood from an intact vessel or an antemortem hospital specimen. There was no uniform death-to-collection interval for the full series.

The upper limit and the dilution workflow

The fentanyl calibration series extended to 40 ng/mL. Above-range specimens could be diluted and reanalyzed, or reported as greater than the upper quantitation limit, with a dilution factor applied where appropriate. Dilution integrity had been validated up to a factor of 20.

There were 614 cases with results above 40 ng/mL, accounting for 14% of the dataset. Seventy were diluted and given quantitative results from 41 to 483 ng/mL. The other 544 were reported semiquantitatively: 540 as greater than 40 ng/mL, and four with higher reported bounds after dilution.

Those four included one result greater than 160 ng/mL, two greater than 200 ng/mL and one greater than 2,000 ng/mL. The last used a dilution factor of 50, outside the study method’s validated dilution factor of 20. The authors retained it as an estimated concentration and acknowledged that limitation.

A bound cannot be treated as a point estimate

Two results reported as greater than 40 ng/mL cannot be ranked by magnitude from that wording alone. One could be modestly above the limit and another substantially higher. Substituting 40 for each result in a calculation would impose an assumption that the report did not establish.

The same caution applies to a result greater than 2,000 ng/mL. It should not be rewritten as exactly 2,000 ng/mL, and its dilution-verification limits must remain visible. The report’s inequality and qualification are part of the scientific result.

The study’s mix of exact and bounded values also matters when comparing averages, concentration distributions or apparent changes over time. A larger extreme value is not necessarily evidence that the typical concentration rose by a corresponding amount. Full specimen-level data and a stated treatment of bounded values would be needed for a new statistical analysis.

Analytical magnitude does not determine cause of death

The case with the estimated result above 2,000 ng/mL also had cocaine at 7.2 mg/L, benzoylecgonine above 20 mg/L and methamphetamine at 0.064 mg/L. Several additional screening findings were unconfirmed. Its cause of death was classified as mixed drug intoxication.

A different case had femoral fentanyl of 400 ng/mL, with methamphetamine, amphetamine and etizolam also detected, but the cause of death was a gunshot wound. Neither case creates a concentration threshold separating fentanyl-caused death from incidental detection. The forensic pathologist used toxicology together with the circumstances and other evidence.

What to retain when reviewing the report

The useful record includes the specimen source, units, calibration limits, actual dilution factor, validation scope and whether the result is exact, estimated or bounded. Screening identification, confirmation and numerical quantitation are separate parts of that record.

These distinctions complement method-specific analytical validation and specimen-specific fentanyl interpretation. A concentration, even when accurately quantified, does not independently establish impairment or causation.

Primary source

Adamo A, Marshall K, Woodall KL. Fentanyl-related deaths in Ontario, Canada: toxicological findings and circumstances of death in 4395 cases (2020–22). Journal of Analytical Toxicology. 2024;48:598–605. https://doi.org/10.1093/jat/bkae061.